Mucosal Delivery of Fentanyl for Pain Management: A Review on Formulation Strategies, Clinical Efficacy, and Safety Considerations

Abstract

Fentanyl, a highly potent synthetic opioid, is widely recognized for its efficacy in managing breakthrough cancer pain—sudden, intense episodes that occur despite ongoing analgesic therapy. Its strong affinity for ?-opioid receptors and rapid onset make it an ideal candidate for transmucosal drug delivery systems, which offer fast, effective pain relief while avoiding the gastrointestinal tract and first-pass hepatic metabolism. Various fentanyl-based mucosal delivery systems have been developed to meet the urgent need for non-invasive, fast-acting pain control. These include oral transmucosal fentanyl citrate (OTFC) lozenges, effervescent buccal tablets, sublingual tablets, sprays, and mucoadhesive buccal films. Each of these formulations is designed to enhance drug solubility, stability, and absorption across the oral mucosa. Among these, effervescent buccal tablets and sublingual formulations show particularly favorable pharmacokinetic profiles, offering faster peak plasma levels and greater bioavailability compared to conventional opioids like morphine. In vitro and pharmacokinetic studies confirm that mucosal systems provide a more consistent and rapid onset of action. These technologies also enhance patient compliance by enabling discreet administration without the need for water or swallowing. Additionally, advancements in excipient selection, permeation enhancers, and pH modulation techniques have significantly improved formulation effectiveness. This review explores the development, evaluation, and clinical performance of fentanyl mucosal delivery systems, emphasizing formulation strategies, safety, and future technological prospects. As research continues, novel approaches such as nanocarrier systems, mucoadhesive patches, and smart drug-delivery platforms may further optimize the management of breakthrough pain, improving both efficacy and patient quality of life.

Keywords

Introduction

Table no. 1: Comparative Features of Mucosal Fentanyl Delivery Systems

Table no.4: Comparative Pharmacokinetic Profile: Effervescent Buccal Tablet vs. OTFC

The combination of faster Tmax and higher Cmax directly correlates with improved onset of analgesia, an essential feature in treating breakthrough pain episodes.

6.2 Clinical Relevance

The design and performance characteristics of FBTs translate into tangible therapeutic advantages:

Table no.5: Clinical Features Supporting FBT Use in Breakthrough Pain

Together, these properties ensure that effervescent buccal tablets provide fast, predictable, and user-friendly fentanyl administration suitable for breakthrough cancer pain management.

7. DISCUSSION

Effervescent buccal tablets exemplify how advanced formulation engineering can translate pharmacologic potential into meaningful clinical benefit. By combining effervescence and dynamic pH modulation, these systems achieve rapid, consistent transmucosal absorption of fentanyl, overcoming many of the limitations associated with conventional oral transmucosal dosage forms. The transient acidification created by citric acid and sodium bicarbonate not only enhances the dissolution rate but also facilitates drug partitioning into the mucosal tissue once the pH returns toward neutrality. This sequential solubilization-permeation mechanism is a key innovation that underpins the improved pharmacokinetic profile observed in comparative studies. Clinically, the faster time to peak concentration (Tmax) and higher systemic exposure enable effervescent buccal tablets to more closely match the temporal pattern of breakthrough cancer pain episodes, which often reach peak intensity within minutes. For patients experiencing frequent, unpredictable pain flares, this rapid onset can improve overall pain control, reduce supplemental opioid use, and enhance quality of life. Despite these advantages, appropriate patient selection, dosing titration, and education remain essential. The high potency of fentanyl increases the risk of unintentional overdose and life-threatening respiratory depression, particularly in opioid-naïve patients or when switching from other fentanyl products. Therefore, prescribers must carefully assess individual opioid tolerance, ensure clear patient instructions on administration, and monitor for adverse effects. In addition, factors such as variability in saliva flow, mucosal health, and tablet dwell time can impact absorption, underscoring the importance of individualized dosing and follow-up. Overall, effervescent buccal tablet formulations represent a promising advancement in the management of breakthrough cancer pain. Their unique combination of formulation science and clinical utility illustrates the value of targeted drug delivery technologies. Continued research into patient-centered design, safety monitoring, and comparative effectiveness will be essential to optimize their role in palliative care and pain management.

8. Future Perspectives

Future innovations may include:

• 3D-printed buccal devices with programmable pH gradients.
• Smart mucoadhesive sensors to monitor dissolution and absorption.
• Combination therapies incorporating non-opioid analgesics.
• Personalized dosing algorithms leveraging pharmacogenomic data.

9. CONCLUSION

Fentanyl effervescent buccal tablets offer a significant advancement in breakthrough pain management by delivering rapid and predictable analgesia. Preformulation and in vitro studies validate their superiority over conventional formulations, demonstrating enhanced transmucosal flux, faster onset of action, and improved bioavailability. The combination of effervescence and dynamic pH modulation not only accelerates dissolution but also facilitates optimal permeation through the buccal mucosa, overcoming solubility limitations inherent to opioid molecules. Furthermore, the mucoadhesive properties of these tablets ensure prolonged contact with the absorption surface, reducing variability associated with salivary dilution and unintentional swallowing. Clinical studies have shown that effervescent buccal tablets achieve higher peak plasma concentrations with shorter Tmax compared to oral transmucosal lozenges, enabling better alignment between drug pharmacokinetics and the episodic nature of breakthrough pain. Importantly, the convenience and discreet administration of buccal tablets improve patient adherence and satisfaction, supporting their integration into palliative care protocols. However, despite these advantages, certain challenges warrant continued attention. Patient selection and individualized dose titration remain critical to mitigate the risks of overdose, respiratory depression, and misuse associated with potent opioids. Future directions in formulation development may include incorporating taste-masking strategies, optimizing disintegration profiles, and exploring novel excipients to further refine the balance between rapid onset and sustained absorption. As mucosal delivery technologies continue to evolve, further optimization in onset, safety, and patient-centric design will enhance therapeutic outcomes and set new standards for opioid-based pain management. This convergence of pharmaceutical innovation and clinical need underscores the importance of interdisciplinary research in achieving effective, safe, and accessible therapies for patients experiencing breakthrough cancer pain.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the support and insights provided by colleagues and mentors in the field of pharmaceutics and pain management.

REFERENCES

1. Göbel, A., da Silva, J. B., Cook, M., & Breitkreutz, J. (2021). Development of buccal film formulations and their mucoadhesive performance in biomimetic models. International Journal of Pharmaceutics, 610, 121233. https://doi.org/10.1016/j.ijpharm.2021.121233
2. da Silva, J. B., Dos Santos, R. S., da Silva, M. B., Braga, G., Cook, M. T., & Bruschi, M. L. (2021). Interaction between mucoadhesive cellulose derivatives and Pluronic F127: Investigation on micelle structure and mucoadhesive performance. Materials Science and Engineering C, 119, 111643. https://doi.org/10.1016/j.msec.2020.111643
3. He, M., Zhu, L., Yang, N., Li, H., & Yang, Q. (2021). Recent advances of oral film as a platform for drug delivery. International Journal of Pharmaceutics, 604, 120759. https://doi.org/10.1016/j.ijpharm.2021.120759
4. Alexander, K. S., Riga, A. T., & Haines, P. J. (2009). Thermoanalytical instrumentation and application. In S. Ahuja & S. Scypinski (Eds.), Ewing’s Analytical Instrumentation Handbook (3rd ed., p. 462). Marcel Dekker.
5. Raju, K. N., Kumar, R. A., Deepika, B., Eswaraiah, M. C., & Rao, A. S. (2012). Formulation and in vitro evaluation of buccal tablets of captopril. International Research Journal of Pharmacy and Applied Sciences, 2(2), 21–43.
6. Weller, P. J. (2009). Handbook of Pharmaceutical Excipients (6th ed., pp. 622–624). Pharmaceutical Press.
7. John, A. S., Sathesh, B. P. R., Divakar, G., Jangid, M. K., & Purohit, K. K. (2010). Development and evaluation of buccoadhesive drug delivery system for atorvastatin calcium. Journal of Current Pharmaceutical Research, 1, 31–38.
8. Darwish, K. M., & Elmeshad, A. N. (2009). Buccal mucoadhesive tablet of flurbiprofen: Characterization and optimization. Drug Discoveries & Therapeutics, 3(4), 181–189.
9. Nair, S. T., Kamalasanan, K., Moidu, A., Shyamsundar, P., Nair, L. J., & Venkatesan, P. (2021). Ethyl cellulose–coated sustained-release aspirin spherules for treating COVID 19: DOE-led rapid optimization using arbitrary interface; applicable for emergency situations. International Journal of Biological Macromolecules, 182, 1769–1784. https://doi.org/10.1016/j.ijbiomac.2021.05.106
10. Perioli, L., Ambrogi, V., Rubini, D., Giovagnoli, S., Ricci, M., Blasi, P., et al. (2004). Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. Journal of Controlled Release, 95, 521–533. https://doi.org/10.1016/j.jconrel.2003.12.023
11. Singh, S., Govind, M., & Bothara, S. B. (2013). A review on in vitro–in vivo mucoadhesive strength assessment. Pharma Tech Medica, 2(1), 211–229.
12. Singh, I., Kumar, P., Kumar, S., & Rana, V. (2010). Formulation and development of matrix tablets of tramadol using katira gum as a release modifier. Yakugaku Zasshi, 130(9), 1225–1231. https://doi.org/10.1248/yakushi.130.1225
13. Techie-Menson, R., Rono, C. K., Etale, A., Mehlana, G., Darkwa, J., & Makhubela, B. C. (2021). New bio-based sustainable polymers and polymer composites based on methacrylate derivatives of furfural, solketal, and lactic acid. Materials Today Communications, 28, 102721. https://doi.org/10.1016/j.mtcomm.2021.102721
14. Obeidat, W. M., Gharaibeh, S. F., Jaradat, A. A., & Abualsuod, O. (2021). Preparation and evaluation of ternary polymeric blends for controlled-release matrices containing a weakly basic model drug. Current Drug Delivery, 18(1), 54–64. https://doi.org/10.2174/1567201817999201207172259
15. Hussein, A. A. (2018). Preparation and evaluation of darifenacin hydrobromide–loaded nanostructured lipid carriers for oral administration. Iraqi Journal of Pharmaceutical Sciences, 27(1), 60–68.
16. Patel, V. F., Liu, F., & Brown, M. B. (2011). Advances in oral transmucosal drug delivery. Journal of Controlled Release, 153(2), 106–116. https://doi.org/10.1016/j.jconrel.2011.01.027
17. Sattar, M., Ahmad, M., Swami, M., & Ali, J. (2014). Buccal mucoadhesive drug delivery: A promising option for orally less bioavailable drugs. Journal of Applied Pharmaceutical Science, 4(2), 45–50.
18. Barnhart, S. D., & Sloboda, M. S. (2009). Transmucosal delivery of fentanyl for acute pain management. Drugs, 69(1), 47–55. https://doi.org/10.2165/00003495-200969010-00004.